Patrick Toomey actually said...
It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.
Context
Toomey argues that Sarbanes-Oxley data is irrelevant for pre-revenue biotech firms.
07/19/2011